Nimbus Therapeutics, Inc.

The stats are known by now: 90% of drug candidates fail during the development process. While artificial intelligence (AI) is touted for its potential to reduce the overall failure rate, a more modest

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

While early 2023 saw COVID-19 finally fading away, other global crises continued throughout the year (Russia-Ukraine invasion) or were newly created (Israel-Hamas conflict). In short, the socioeconomi

There are a few candidates with the potential to join Bristol Myers Squibb Company ’s Sotyktu in the TYK2 inhibitor space but Ventyx Biosciences, Inc. 's VTX958 is no longer one of them. The San Die